RESEARCH TRIANGLE PARK, NC--(Marketwired - May 21, 2015) - Life sciences companies generally discount the value of patient-reported outcomes (PROs) in favor of quantitative clinical results. However, according to a study by business intelligence firm Cutting Edge Information, these self-reported outcomes are an important indicator of a drug's potential for future success.

Regardless of a product's clinical performance, a patient will be reluctant to comply with a regimen that is difficult to follow or that negatively impacts his or her quality of life. And, with non-adherence costing the US healthcare system up to an estimated $289 billion each year, payers are looking for PROs when comparing drugs for formulary position.

"In an era of increasing competition and rising payer demands, capturing the patient voice is crucial," said Victoria Cavicchi, research analyst at Cutting Edge Information. "Companies that incorporate patient-reported outcomes into their value propositions may find themselves better situated for reimbursement and approval discussions."

More articles about

Newswire Distribution Network & Management

About Us

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.